ALDH2 stable expression cell line, construction method and application

By constructing a cell line with stable expression of ALDH2, the problem of different effects of existing agonists and inhibitors was solved, and the stable regulation of ALDH2 activity or expression was achieved, and a reliable cell model for studying RILI was provided, which alleviated radioactive lung injury. The impact of

CN119082043APending Publication Date: 2024-12-06Zhangjiajie University +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411405589.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-10
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing agonists and inhibitors have mixed effects in regulating ALDH2 activity or expression, and are costly and difficult to repeat experimental results, resulting in difficulties in preventing and treating radioactive lung injury (RILI).

Method used

ALDH2-stable cell line was constructed, and ALDH2 was overexpressed or underexpressed by unique plasmid and target selection binding construction process and parameter control were achieved. A549 cells were transfected with recombinant plasmids EX-C0231-Lv206 and HSH095660-LVRU6MP-e. Puromycin screening achieved a transfection efficiency of 90% and stable expression.

Benefits of technology

The stable regulation of ALDH2 activity or expression was achieved, and instead of agonists and inhibitors, providing a reliable cellular model for studying the mechanism of ALDH2 on radioactive lung injury and the development of related drugs to effectively alleviate RILI.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082043A_ABST
    Figure CN119082043A_ABST
Patent Text Reader

Abstract

The invention discloses a cell line with stable expression of ALDH2. The cell line comprises a cell line with over-expression of ALDH2 and a cell line with knock-down of ALDH2. The nucleotide sequence of the ALDH2 is as shown in SEQ ID NO: 1; wherein the ALDH2 overexpressed cell line comprises a recombinant plasmid EX-C0231-Lv206 of which the nucleotide sequence is as shown in SEQ ID NO: 2; wherein the ALDH2 knock-down cell line comprises a recombinant plasmid HSH095660-LVRU6MP-e, and the nucleotide sequence of the recombinant plasmid HSH095660-LVRU6MP-e is shown as SEQ ID NO: 3. The ALDH2 stable expression cell line disclosed by the invention can be beneficial to stable overexpression or low expression of ALDH2, so that the activity or expression of ALDH2 is increased or reduced to form contrast, and the ALDH2 stable expression cell line can replace the existing agonist and inhibitor.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of cell line construction, and in particular to a cell line stably expressing ALDH2, a construction method and an application thereof. Background Art

[0002] Lung cancer refers to a malignant tumor that originates from the bronchial mucosa or glands of the lungs. In recent years, the number of treatments for lung cancer has increased, among which radiotherapy (abbreviated as radiotherapy) is an irreplaceable and effective means. It achieves the purpose of eliminating tumor cells by directly causing the DNA structure of tumor cells to break and indirectly causing water molecules in tumor cells to form free radicals to kill cells. However, the side effects associated with radiotherapy for lung cancer have also attracted people's attention. Radiation-induced lung injury (RILI) is one of these side effects, and its incidence varies depending on different diagnostic criteria. Once this happens, it will limit the dose of radiotherapy, affect the treatment effect, and increase the economic and mental burden of patients. Therefore, the prevention and treatment of RILI is urgent.

[0003] In recent years, more and more studies have reported that mutant ALDH2 can affect the occurrence and progression of a variety of diseases. For example, cardiovascular disease, neurodegenerative diseases, liver and lung diseases. In lung diseases, researchers have found that stimulating ALDH2 activity can improve rat lung ischemia-reperfusion injury and air embolism-induced lung injury, reduce inflammatory response and pathological lesions, and therefore, researchers have conducted further in-depth research on this. However, at present, the role of ALDH2 on RILI and its mechanism are still unclear, and it is still a difficult point in research and development.

[0004] In addition, in the process of exploring the role of ALDH2 in RILI and its mechanism, the activity or expression of ALDH2 needs to be increased or decreased to form a comparison. Previously, most scholars often used agonists or inhibitors to increase or decrease ALDH2 activity when studying the role of ALDH2 in a certain disease. The applicant also adopted this approach in the previous research. However, in actual application, the effects of agonists and inhibitors of various brands vary, and the drugs are expensive, making it inconvenient to repeatedly reproduce the experimental results. Therefore, it is urgent to establish a cell line with stable expression of ALDH2, which is of great practical significance. Summary of the invention

[0005] The technical problem solved by the present invention is to provide a cell line with stable expression of ALDH2, which is conducive to stable overexpression or low expression of ALDH2, thereby achieving an increase or decrease in the activity or expression of ALDH2 to form a comparison, so as to replace the use of existing agonists and inhibitors.

[0006] The second technical problem solved by the present invention is to provide a method for constructing a cell line with stable expression of ALDH2, which obtains an A549 cell line with stable expression of ALDH2 by constructing a unique plasmid and selecting a target, combined with a unique construction process and parameter control.

[0007] The third technical problem solved by the present invention is to provide the application of the cell line in the mechanism of ALDH2 improving radiation lung injury drugs and related drugs.

[0008] The technical problem solved by the present invention is achieved by adopting the following technical solutions:

[0009] A cell line stably expressing ALDH2, including a cell line overexpressing ALDH2 and a cell line knocking down ALDH2; the nucleotide sequence of ALDH2 is shown in SEQ ID NO: 1;

[0010] The ALDH2 overexpressing cell line includes the recombinant plasmid EX-C0231-Lv206 with a nucleotide sequence as shown in SEQ ID NO: 2;

[0011] The ALDH2 knockdown cell line includes the recombinant plasmid HSH095660-LVRU6MP-e whose nucleotide sequence is shown in SEQ ID NO:3.

[0012] Furthermore, the cell line is A549 cell line.

[0013] Furthermore, the recombinant plasmid EX-C0231-Lv206 was constructed by recombining the ALDH2 gene with the pEZ-Lv206 eukaryotic expression vector.

[0014] Furthermore, the recombinant plasmid HSH095660-LVRU6MP-e was constructed by recombining the ALDH2 gene with the psi-LVRU6MP eukaryotic expression vector, and the nucleotide sequence of its short hairpin shRNA is shown in SEQ ID NO:4.

[0015] Furthermore, the recombinant plasmid EX-C0231-Lv206 and the recombinant plasmid HSH095660-LVRU6MP-e both include the mcherry reporter gene and the puro resistance gene.

[0016] The method for constructing a cell line with stable expression of ALDH2 as described above is characterized by comprising: transfecting A549 cells with the recombinant plasmid EX-C0231-Lv206 or the recombinant plasmid HSH095660-LVRU6MP-e; and screening with puromycin at a concentration of 1.5 to 2.5 μg / mL to obtain a cell line with stable overexpression or knockdown of ALDH2.

[0017] Furthermore, the transfection is performed by liposome method, and the transfection efficiency is ≥90%.

[0018] Furthermore, during screening, 1.5-2.5 μg / mL of puromycin was used for preliminary screening within 24-48 hours after transfection; after 48 hours, the transfected cells were continuously screened and amplified every 3-5 days using half the concentration of the previous puromycin until the fluorescence expression of A549 cells reached 80-90%.

[0019] Use of any of the above cell lines in the ALDH2 drug to improve radiation-induced lung injury.

[0020] Furthermore, in the radiation-induced lung injury drug, ALDH2 alleviates RILI by inhibiting ROS and EMT mediated by the TGF-β1 / Smad pathway.

[0021] Beneficial effects: The cell line stably expressing ALDH2 described in the present invention uses recombinant plasmid EX-C0231-Lv206 and recombinant plasmid HSH095660-LVRU6MP-e as gene vectors to transfect cells to obtain a cell line stably expressing ALDH2, which can facilitate stable overexpression or low expression of ALDH2, thereby achieving an increase or decrease in the activity or expression of ALDH2 to form a comparison, and can replace the use of existing agonists and inhibitors.

[0022] The ALDH2 stably expressed cell line of the present invention uses recombinant plasmids EX-C0231-Lv206 and HSH095660-LVRU6MP-e, both of which include an mcherry reporter gene and a puro resistance gene. The mcherry reporter gene causes the cells to emit red fluorescence after successful transfection, which is convenient for observing and evaluating the transfection efficiency and laying a foundation for subsequent successful construction, while the puro resistance gene is conducive to efficient screening.

[0023] The method for constructing a cell line with stable expression of ALDH2 of the present invention combines unique construction steps and parameters through the construction of a unique plasmid and target selection, and further adds a reporter gene, so that the transfection efficiency is as high as 90% and the screening is convenient, thereby obtaining an A549 cell line with stable expression of ALDH2.

[0024] The cell line with stable expression of ALDH2 of the present invention can be well applied to ALDH2 drugs and drug research for improving radiation-induced lung injury. And the present invention has found that ALDH2 in radiation-induced lung injury drugs can reduce RILI by inhibiting ROS and EMT mediated by TGF-β1 / Smad pathway. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1This is the structure diagram of the ALDH2 overexpression plasmid pEZ-Lv206 vector.

[0026] Figure 2 This is the structure diagram of the LDH2 knockdown plasmid psi-LVRU6MP vector.

[0027] Figure 3 The diagram shows qPCR verification of plasmid effects and screening of the best knockdown targets.

[0028] Figure 4 549 cells (4×10) were transfected with various plasmids.

[0029] Figure 5 The figure shows the expression of EMT markers.

[0030] Figure 6 This is a graph showing the effect of ALDH2 on ROS levels in A549 cells after irradiation.

[0031] Figure 7 This graph shows the effect of ALDH2 on the levels of IL-6, TGF-β1, and TNF-α in A549 cells after irradiation.

[0032] Figure 8 This is a diagram showing the effect of ALDH2 on the TGF-β1 / Smad pathway. DETAILED DESCRIPTION

[0033] In order to make the technical means, creative features, objectives and effects achieved by the present invention easy to understand, the present invention is further described below in conjunction with specific embodiments.

[0034] (I) The cell lines stably expressing ALDH2 described in the present invention include cell lines overexpressing ALDH2 and cell lines knocking down ALDH2. The nucleotide sequence of ALDH2 is shown in SEQ ID NO: 1; preferably, the cell line is an A549 cell line. The human non-small cell lung cancer cell line A549 cells in the embodiment of the present invention are commercially available products. The cells are cultured in a cell culture incubator at 37°C, containing 5% CO2, 95% air and appropriate humidity. The cells are cultured using RPMI-1640 complete medium. When the cells grow to 80-90%, they are subcultured at a ratio of 1:3-1:4.

[0035] The ALDH2 overexpressing cell line includes a recombinant plasmid EX-C0231-Lv206 with a nucleotide sequence as shown in SEQ ID NO: 2; the recombinant plasmid EX-C0231-Lv206 is constructed by recombining the ALDH2 gene with the pEZ-Lv206 eukaryotic expression vector. The structure of the pEZ-Lv206 eukaryotic expression vector is as follows Figure 1 shown.

[0036] The ALDH2 knockdown cell line includes the recombinant plasmid HSH095660-LVRU6MP-e with a nucleotide sequence as shown in SEQ ID NO: 3. The recombinant plasmid HSH095660-LVRU6MP-e is constructed by recombining the ALDH2 gene with the psi-LVRU6MP eukaryotic expression vector. The structure of the psi-LVRU6MP eukaryotic expression vector is as shown in Figure 2 The nucleotide sequence of the short hairpin shRNA is shown in SEQ ID NO:4.

[0037] In this example, for control, a recombinant plasmid HSH095660-LVRU6MP-c with a nucleotide sequence as shown in SEQ ID NO:5 in an ALDH2 knockdown cell line using a different C target, and a nucleotide sequence of its short hairpin shRNA as shown in SEQ ID NO:6. And for control, a recombinant plasmid HSH095660-LVRU6MP-f with a nucleotide sequence as shown in SEQ ID NO:7 in an ALDH2 knockdown cell line using a different F target, and a nucleotide sequence of its short hairpin shRNA as shown in SEQ ID NO:8.

[0038] (ii) The method for constructing the cell line stably expressing ALDH2 described in the present invention.

[0039] The configuration of the main reagents involved in the present invention is as follows. Other reagents involved are actually purchased through conventional commercial channels or configured in conventional laboratories, which will not be described in detail here:

[0040] RPMI-1640 complete medium: RPMI-1640 basal medium 500mL + blue chain double antibody 5mL + fetal bovine serum 50mL

[0041] TBST: TBS dry powder + 2L first-grade water + 2mL Tween-20;

[0042] Preparation of puromycin working concentration: Dissolve 25 mg puromycin powder in 500 μl sterile first-grade water, filter through a 0.22 μm filter membrane to prepare a 50 mg / mL stock solution, store in aliquots at -20°C in the dark, and dilute to the working concentration with RPMI-1640 complete medium when used.

[0043] The primer sequences used are as follows:

[0044] Forward primer (5'-3'): GAATTTCCCGCTCCTGATGCAA

[0045] Reverse primer (3'-5'): ACCTTCATCACAACCACGTTT

[0046] The construction method is as follows:

[0047] 1) Cell transfection:

[0048] The A549 cells in good condition were digested, resuspended and evenly plated in a 6-well plate, so that the number of cells could grow to 70-80% of the volume of the well plate. At this time, the cells were grouped into: Control group (normal A549 cells without transfection), OE-NC group (A549 cells transfected with ALDH2 overexpression control plasmid, the nucleotide sequence of the control plasmid is shown in SEQ ID NO:9), OE group (A549 cells transfected with ALDH2 overexpression plasmid) or Control group (normal A549 cells without transfection), Sh-NC group (A549 cells transfected with ALDH2 knockdown control plasmid, the nucleotide sequence of the control plasmid is shown in

[0049] SEQ ID NO:9), Sh-C group (A549 cells transfected with ALDH2 C target knockdown plasmid), Sh-E group (A549 cells transfected with ALDH2 E target knockdown plasmid), Sh-F group (A549 cells transfected with ALDH2 F target knockdown plasmid).

[0050] Before transfection, discard the old culture medium, rinse the cells with PBS 1-2 times, use the pipette tip to suck out the excess liquid, replace with culture medium containing antibiotics and serum, and place in the incubator for use.

[0051] Take 12 1.5mL EP tubes and add 100μl of reduced serum medium to each tube according to the instructions of Lipo2000. Add 2.5μg plasmid to half of the EP tubes, and the required plasmid volume (μl) = 2.5μg / plasmid concentration (ng / μl). Add Lipo 2000 and reduced serum to the other half of the EP tubes according to the optimal plasmid transfection ratio obtained in the preliminary experiment. Transfer the reduced serum medium containing plasmid to the tube containing transfection reagent, mix carefully and gently by pipetting 3-5 times, and let it stand for 30min-1h;

[0052] When the time is up, take out the well plate to be transfected from the incubator, aspirate the mixed solution in the EP tube, drip it evenly into the well plate from the top in a clockwise direction, shake it gently, and continue to put it in the incubator.

[0053] After 4-6 hours, observe the cell survival under a microscope, and then replace the culture medium with the culture medium required for normal culture. After 24 hours of normal culture, the transfection status can be observed under a fluorescence microscope.

[0054] 2) Screening: Observe the red fluorescence under a fluorescence microscope 24 hours after transfection. If the number of fluorescent cells is small, screening can be performed again after 48 hours. After successful transfection, replace the cell culture medium with a complete culture medium containing 2 μg / mL puromycin; stop screening after 48 hours, wash the cells with PBS, digest them with trypsin and move them to a T25 bottle; continue to screen and amplify the transfected cells every 3-5 days using half the original concentration of puromycin until the fluorescence expression of A549 cells reaches 80-90%.

[0055] Before the screening step, a test to determine the optimal concentration of puromycin for stable screening is required:

[0056] At 24 hours after adding puromycin of different working concentrations to normal A549 cells, cells in all concentration groups survived; at 48 hours, cells in the 2, 4, 6, and 8 μg / mL concentration groups all died (results are shown in Table 1). Therefore, in this embodiment, 2 μg / mL of puromycin was used as the subsequent stable cell line screening concentration.

[0057] Table 1 Puromycin stable screening optimal concentration cell survival observation table

[0058]

[0059] (- represents cells not dead, + represents less than 50% cell death, ++ represents all cell death)

[0060] qPCR verification of plasmid effects and screening of optimal knockdown targets:

[0061] Pre-transfection test: A549 cells in good condition were digested, resuspended and evenly plated into 6-well plates, so that the number of cells could grow to 70-80% of the volume of the well plate. At this time, the cells were grouped as follows: Control group (normal A549 cells without transfection), OE-NC group (A549 cells transfected with ALDH2 overexpression control plasmid, the nucleotide sequence of the control plasmid is shown in SEQ ID NO: 9), OE group (A549 cells transfected with ALDH2 overexpression plasmid) or Control group (normal A549 cells without transfection), Sh-NC group (A549 cells transfected with ALDH2 knockdown control plasmid, the nucleotide sequence of the control plasmid is shown in SEQ ID NO: 9), Sh-C group (A549 cells transfected with ALDH2 C target knockdown plasmid), Sh-E group (A549 cells transfected with ALDH2 E target knockdown plasmid), Sh-F group (A549 cells transfected with ALDH2 F target knockdown plasmid).

[0062] Before transfection, discard the old culture medium, rinse the cells with PBS 1-2 times, use the pipette tip to suck out the excess liquid, replace with culture medium containing antibiotics and serum, and place in the incubator for use.

[0063] Take 12 1.5mL EP tubes and add 100μl of reduced serum medium to each tube according to the instructions of Lipo2000. Add 2.5μg plasmid to half of the EP tubes, and the required plasmid volume (μl) = 2.5μg / plasmid concentration (ng / μl). Add Lipo 2000 and reduced serum to the other half of the EP tubes according to the optimal plasmid transfection ratio obtained in the preliminary experiment. Transfer the reduced serum medium containing plasmid to the tube containing transfection reagent, mix carefully and gently by pipetting 3-5 times, and let it stand for 30min-1h;

[0064] When the time is up, take out the well plate to be transfected from the incubator, aspirate the mixed solution in the EP tube, drip it evenly into the well plate from the top in a clockwise direction, shake it gently, and continue to put it in the incubator.

[0065] After 4-6 hours, observe the cell survival under a microscope, and then replace the culture medium with the culture medium required for normal culture. After 24 hours of normal culture, the transfection status can be observed under a fluorescence microscope.

[0066] The plasmid effect was verified by qPCR and the best knockdown target was screened. The results are as follows:

[0067] Table 2 ALDH2 overexpression plasmid qPCR data

[0068]

[0069] Table 3 qPCR data of ALDH2 knockdown plasmids at different targets

[0070]

[0071] △Ct, -△△Ct and 2 in Table 2 and Table 3 -△△Ct All are the average values ​​of the corresponding indicators after three repetitions. Under normal circumstances, ΔCt of a single sample = Ct of the target gene - Ct of the internal reference gene, -ΔΔCt = (control group) ΔCt - ΔCt of each sample, 2 -ΔΔCt Reflects the ratio of the target gene expression level of each sample relative to the control group sample.

[0072] Figure 3A is the qPCR amplification curve after ALDH2 overexpression plasmid transfection; B is the qPCR melting curve after ALDH2 overexpression plasmid transfection; C is the qPCR amplification curve after ALDH2 different target knockdown plasmid transfection; D is the qPCR melting curve after ALDH2 different knockdown target plasmid transfection; E is the qPCR result histogram after ALDH2 overexpression plasmid transfection; Compared with the Control group, *P<0.05, n=3. Compared with the OE-NC group, &P<0.05, n=3; F is the qPCR result histogram after ALDH2 different knockdown target plasmid transfection. Compared with the Control group, *P<0.05, n=3; Compared with the knockdown empty load group (Sh-NC), &P<0.05, n=3.

[0073] As shown in Table 2, Table 3 and Figure 3 As shown in the figure, in the overexpression group, compared with the Control, there was no significant difference in the ALDH2 mRNA expression in the OE-NC group and the Sh-NC group (P>0.05), and in the OE group, the ALDH2 mRNA expression was significantly increased (P<0.05). In the knockdown group, the ALDH2 expression in the Sh-C, E, and F groups decreased to varying degrees, among which the Sh-E group had the most obvious effect (P<0.0 5), and the knockdown efficiency reached more than 80%, which can continue to be used to construct stable cell lines.

[0074] The results of cell transfection efficiency in each group are shown in Figure 4 As shown: The transfected cells were observed under an inverted fluorescence microscope, and red fluorescence was visible from the cells. The cells were counted in the photographs taken using Image J software, and the transfection efficiency was calculated according to the formula: transfection efficiency = number of luminescent cells in the same visual field / total number of cells in the same visual field × 100%. The calculation showed that the transfection efficiency of each group of cells was about 90%.

[0075] Western blot detection of each group: Western blot detection was performed on the transfected A549 cells. The results are as follows Figure 5 As described above, it can be seen that compared with the OE-NC group, the ALDH2 protein level in the OE group increased (P<0.05); compared with the Sh-NC group, the ALDH2 protein expression level in the Sh-NC group decreased (P<0.05). Both results indicate that the A549 stable cell line with ALDH2 overexpression and knockdown was successfully established.

[0076] ALDH2 is one of the important enzymes in the human body. Its main function is to catalyze the metabolism of aldehydes in vivo and in vitro into acetic acid. The decrease or loss of ALDH2 activity will have a certain impact on the human body, increasing susceptibility to some diseases, including some inflammatory injuries, fibrotic diseases, etc. In exploring the role of ALDH2 in RILI, it is extremely critical and important to increase or decrease the activity or expression of ALDH2 in A549 to form a comparison. In the prior art, most agonists and inhibitors are used to increase or decrease the activity of ALDH2, but the effects of products from various brands vary, and the drugs are expensive, making it inconvenient to repeatedly reproduce the experimental results. Because the construction of an A549 cell line with stable expression of ALDH2 is the focus of the research and development of the present invention.

[0077] In the present invention, a recombinant plasmid is used as a gene vector, and the target gene is delivered into the cell by liposome transfection. During the experiment, it was found that the qPCR results showed that the mRNA content of ALDH2 increased significantly after transfection with a specific overexpression plasmid, and improper plasmid selection could not achieve the desired effect. Similarly, the expression levels of each knockdown plasmid decreased, but only the E target had the best knockdown effect, which reduced the expression of the target gene by 80% compared with the Control group or Sh-NC group. This target was used in the subsequent stable system construction of the knockdown group, indicating that the target of the recombinant plasmid is extremely critical.

[0078] In addition, a high transfection efficiency is not only a prerequisite for verifying the quality of the plasmid, but is also very necessary for increasing the success rate of stable cell line construction. The plasmid used in the present invention is designed with an mCherry reporter gene, which prompts the cells after successful transfection to emit red fluorescence, making it easy for people to observe and evaluate the transfection efficiency. The fluorescence luminescence is observed under a fluorescence microscope 24 hours after transfection, and the transfection efficiency of the cells is estimated to be about 90% through software calculation, which lays a foundation for subsequent successful construction.

[0079] The plasmid used in the present invention carries a puromycin resistance gene, and the optimal screening concentration of puromycin is determined by preliminary experiments. The results show that 2 μg / mL of puromycin can kill all untransfected cells at 48h without affecting the cells that are successfully transfected, so that the cells that are successfully transfected and untransfected can be fully distinguished, which is one of the key conditions for building a stable cell line. In addition, during the experiment, shortly after the first use of puromycin screening, the original number of luminescence will gradually decrease and reach a "trough", which may be because the target gene is not truly integrated into the DNA of the host cell and is lost as the cell divides and dies. Under the continuous and intermittent creative use of the original 1 / 2 puromycin concentration screening, the cells gradually recover and grow in a central divergent cluster, and the cells can grow all over the well plate in about 1 month. It was observed that the cells all showed red fluorescence under a fluorescence microscope, and WB detection found that the ALDH2 protein expression level of the OE group was significantly higher than that of the OE-NC group, while that of the Sh-E group was significantly lower than that of the Sh-NC group, proving that the stable system was successfully constructed.

[0080] In summary, the present invention successfully constructed a cell line with stable overexpression or underexpression of ALDH2, which has important research and development significance.

[0081] (III) ALDH2 alleviates RILI by inhibiting ROS and EMT mediated by the TGF-β1 / Smad pathway.

[0082] The ALDH2 overexpression and underexpression A549 cell lines successfully constructed by the present invention and the normally cultured A549 cells were used for further experimental verification.

[0083] 1. Cell grouping and irradiation

[0084] The stably transfected cells were divided into Control group (normal cultured A549 cells), IR group (normal cultured A549 cells + irradiation), IR+OE-NC group (ALDH2 overexpression empty control stable cell line + irradiation), IR+OE group (ALDH2 overexpression stable cell line + irradiation) or Control group, IR group, IR+Sh-NC group (ALDH2 knockdown empty control stable cell line + irradiation), and IR+Sh-E group (ALDH2 knockdown stable cell line + irradiation).

[0085] Each group of cells was inoculated into a 24-well plate at 1×105 cells / mL and irradiated with 6MV X-rays once, with a dose rate of 200 cGy / min, a gantry angle of 180°, and the rays were irradiated upward from the bottom of the culture dish or well plate. The total irradiation dose was 10 Gy, and the source-skin distance was 100 cm.

[0086] 2. qPCR was used to detect the mRNA expression levels of EMT markers E-Cadherin and N-Cadherin in each group of cells.

[0087] The results are as follows Figure 5 As shown, A is the expression level of EMT marker mRNA after transient transfection of ALDH2 overexpression plasmid. Compared with the Control group, *P<0.05, compared with the OE-NC group, &P<0.05, n=3. B is the expression level of EMT marker mRNA after transient transfection of ALDH2 knockdown plasmid. Compared with the Control group, *P<0.05, compared with the OE-NC group,

[0088] &P<0.05, n=3. C shows the effect of ALDH2 overexpression on radiation-induced EMT. Compared with the Control group, *P<0.05, compared with the IR group, &P<0.05, n=3. D shows the effect of ALDH2 knockdown on radiation-induced EMT. Compared with the Control group, *P<0.05, compared with the IR group, &P<0.05, n=3.

[0089] It can be seen that compared with the Control group, the expression level of E-Cadnherin mRNA in the OE group was significantly increased (P<0.05), while the level of N-Cadherin mRNA was significantly decreased (P<0.05) (see Figure 3-2 -A); In contrast to the OE group, the N-Cadherin mRNA expression level in the Sh-E group was increased (P<0.05), while the E-Cadherin mRNA level was significantly decreased (P<0.05) compared with the Control group (see Figure 3-2 -B); OE-NC, Sh-NC group and Control group were not statistically significant. We then irradiated the A549 cells with stable expression and then detected EMT markers. Similarly, we found that compared with the Control group, the epithelial marker E-Cadherin decreased to varying degrees in each group after irradiation, while N-Cadherin increased. Compared with the IR group, the degree of EMT in the IR+OE group was milder (P<0.05), while that in the IR+Sh-E group was more severe (P<0.05).

[0090] 3. Use a fluorescent microplate reader to detect the reactive oxygen species (ROS) content of each group of cells.

[0091] The results are as follows Figure 6As shown, A shows the effect of ALDH2 overexpression on ROS level in A549 cells after irradiation. Compared with the Control group, *P<0.05, compared with the IR group, &P<0.05, n=4. B shows the effect of ALDH2 knockdown on ROS level in A549 cells after irradiation. Compared with the Control group, *P<0.05, compared with the IR group, &P<0.05, n=4.

[0092] It can be seen that compared with the Control group, the ROS levels of each group after radiation exposure increased to varying degrees (P<0.05). Compared with the IR group, there was no significant difference in the IR+OE-NC group and the IR+Sh-NC group (P>0.05), the ROS level of the IR+OE group decreased (P<0.05), and the opposite was true for the IR+Sh-E group (P<0.05).

[0093] 4. Enzyme-linked immunosorbent assay (ELISA) was used to detect the content of IL-6, TNF-α, and TGF-β1 in each group of cells after irradiation. The results are shown in Table 7.

[0094] Figure 7 A and B show the effects of ALDH2 overexpression and knockdown on IL-6 levels in A549 cells after irradiation. Compared with the Control group, *P<0.05, compared with the OE-NC group, &P<0.05, n=4. C and D show the effects of ALDH2 overexpression and knockdown on TNF-α levels in A549 cells after irradiation. Compared with the Control group, *P<0.05, compared with the OE-NC group, &P<0.05, n=4. E and F show the effects of ALDH2 overexpression and knockdown on TGF-β1 levels in A549 cells after irradiation. Compared with the Control group, *P<0.05, compared with the OE-NC group, &P<0.05, n=4.

[0095] It can be seen that compared with the Control group, the levels of IL-6, TGF-β1, and TNF-α in each group after radiation irradiation increased to varying degrees (P<0.05). Compared with the IR group, there was no significant difference in the IR+OE-NC group and the IR+Sh-NC group (P>0.05), the levels of IL-6, TGF-β1, and TNF-α in the IR+OE group decreased (P<0.05), and the opposite was true in the IR+Sh-E group (P<0.05).

[0096] 5. To verify the effect of ALDH2 on TGF-β1 / Smad pathway, Western Blot was used to detect the expression of TGF-β1 / Smad pathway marker proteins in each group after irradiation.

[0097] The results are as follows Figure 8As shown, A shows the effect of ALDH2 overexpression on TGF-β1 / -Smad pathway. Compared with the Control group, *P<0.05, compared with the OE-NC group, &P<0.05, n=3. B shows the effect of ALDH2 knockdown on TGF-β1 / Smad pathway. Compared with the Control group, *P<0.05, compared with the OE-NC group, &P<0.05, n=3.

[0098] It can be seen that compared with the Control group, the P-Smad protein levels in the other groups were increased. Compared with the IR group, the expression level of P-Smad2 / 3 protein in the IR+OE group was lower (P<0.05), while the opposite was true in the IR+Sh-E group (P<0.05).

[0099] In summary, excessive production of ROS is an important feature of the pathological process of RILI. The role of ROS runs through the entire process of RILI, and inhibiting the excessive generation of ROS is one of the important strategies for the treatment of RILI. In the present invention, compared with the Control group, the ROS levels of A549 cells in each group after irradiation with a total dose of 10Gy increased. Compared with the IR group, the ROS level of the OE group was significantly reduced, while that of the Sh-E group was significantly increased. This shows that ALDH2 overexpression can protect RILI by inhibiting ROS.

[0100] Another characteristic of RILI is the massive release of inflammatory factors. However, there are many inflammatory factors in the human body. After verification, it was found that compared with the Control group, all groups showed an upward trend. Compared with the IR group, the content of each inflammatory factor in the OE group was lower, while the Sh-E group showed the opposite trend. This shows that ALDH2 affects RILI by regulating the level of inflammatory factors.

[0101] In the middle and late stages of RILI, EMT will occur. EMT refers to the biological process in which the body is stimulated by various factors and epithelial cells lose their original characteristics (loss of cell-cell adhesion and apical-basal polarity) and transform into mesenchymal phenotype cells with migration and invasion capabilities. The characteristics of EMT include the reduction of epithelial markers such as E-cadherin and high expression of mesenchymal markers such as N-cadherin and vimentin. According to existing studies, EMT can be mediated by multiple signaling pathways, but EMT promotes repair or fibrosis mainly triggered by pathways such as TGF-β1 / Smad, MAPK, and PI3K. In the present invention, it has been proved by experiments that ALDH2 can alleviate RILI by inhibiting EMT mediated by the TGF-β1 / Smad signaling pathway.

[0102] In summary, ALDH2 alleviates RILI by inhibiting ROS and inflammatory factor levels and regulating EMT mediated by the TGF-β1 / Smad pathway. This mechanism can be well applied to the development of RILI therapeutic drugs.

[0103] The above shows and describes the basic principles, main features and advantages of the present invention. It should be understood by those skilled in the art that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, which fall within the scope of the present invention to be protected. The scope of protection of the present invention is defined by the attached claims and their equivalents.

Claims

1. A cell line stably expressing ALDH2, characterized in that: Including ALDH2 overexpressing cell lines and ALDH2 knockdown cell lines; the nucleotide sequence of ALDH2 is shown in SEQ ID NO: 1; The ALDH2 overexpressing cell line includes the recombinant plasmid EX-C0231-Lv206 with a nucleotide sequence as shown in SEQ ID NO: 2; The ALDH2 knockdown cell line includes the recombinant plasmid HSH095660-LVRU6MP-e whose nucleotide sequence is shown in SEQ ID NO:

3.

2. The cell line stably expressing ALDH2 according to claim 1, characterized in that: The cell line is A549 cell line.

3. The cell line stably expressing ALDH2 according to claim 2, characterized in that: The recombinant plasmid EX-C0231-Lv206 was constructed by recombining the ALDH2 gene with the pEZ-Lv206 eukaryotic expression vector.

4. The cell line stably expressing ALDH2 according to claim 2, characterized in that: The recombinant plasmid HSH095660-LVRU6MP-e is constructed by recombination of the ALDH2 gene and the psi-LVRU6MP eukaryotic expression vector, and the nucleotide sequence of its short hairpin shRNA is shown in SEQ ID NO:

4.

5. The cell line stably expressing ALDH2 according to claim 2, characterized in that: The recombinant plasmid EX-C0231-Lv206 and the recombinant plasmid HSH095660-LVRU6MP-e both include the mcherry reporter gene and the puro resistance gene.

6. The method for constructing a cell line stably expressing ALDH2 according to any one of claims 1 to 5, characterized in that: include: A549 cells were transfected with recombinant plasmid EX-C0231-Lv206 or recombinant plasmid HSH095660-LVRU6MP-e; and puromycin at a concentration of 1.5 to 2.5 μg / mL was used for screening to obtain cell lines with stable overexpression or knockdown of ALDH2.

7. The method for constructing a cell line stably expressing ALDH2 according to claim 6, characterized in that: The transfection was performed by liposome method, and the transfection efficiency was ≥ 90%.

8. The method for constructing a cell line stably expressing ALDH2 according to claim 6, wherein: During screening, 1.5-2.5 μg / mL puromycin was used for preliminary screening within 24-48 hours after transfection; after 48 hours, the transfected cells were screened and amplified every 3-5 days using half the concentration of the previous puromycin until the fluorescence expression of A549 cells reached 80-90%.

9. Use of the cell line according to any one of claims 1 to 5 in a drug for improving radiation-induced lung injury by ALDH2.

10. The use according to claim 9, characterized in that ALDH2 alleviates RILI by inhibiting ROS and EMT mediated by the TGF-β1 / Smad pathway.

Citation Information

Patent Citations

  • Compositions and methods for inhibiting ALDH2 expression

    CN111601891A

  • Tumor signature for metastasis, compositions of matter methods of use thereof

    US20200071773A1